MetaStat, Inc. (OTCQB: MTSTD) is a molecular diagnostic company that develops and commercializes best-in-class diagnostic tests for the early and reliable prediction and treatment of systemic metastasis, the process by which cancer spreads from a primary tumor through the bloodstream to other areas of the body. MetaStat is focused on breast, prostate, lung and colorectal cancers, where systemic metastasis is responsible for approximately 90% of all deaths. The Company’s epigenetic-based diagnostic platform is built on the identification and understanding of the tumor microenvironment and pivotal role of the Mena protein and its isoforms, a common pathway for the development of systemic metastatic disease in all epithelial-based solid tumors. Both the MetaSite Breast™ and MenaCalc™ assays are designed to accurately stratify patients based on their individual risk of metastasis and to provide physicians and patients with clinically actionable information to better "customize" cancer treatment. MetaStat’s testing platform improves treatment planning decisions by positively identifying patients with a high-risk of metastasis who need aggressive therapy and by sparing patients with a low-risk of metastasis from the harmful side effects and expense of chemotherapy.
MetaStat’s head office and diagnostic laboratory are located in Boston, MA.
2014 - Journal of the National Cancer Institute - Rohan et al.